tiprankstipranks
Trending News
More News >
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
Advertisement

Iovance Biotherapeutics (IOVA) AI Stock Analysis

Compare
3,614 Followers

Top Page

IOVA

Iovance Biotherapeutics

(NASDAQ:IOVA)

Rating:49Neutral
Price Target:
$4.00
▲(0.76%Upside)
Iovance Biotherapeutics presents a mixed investment case. While recent revenue growth and strategic corporate developments are promising, ongoing profitability challenges and valuation concerns weigh heavily. Technical indicators suggest the stock is overbought, and the earnings call highlighted both opportunities and ongoing operational issues.
Positive Factors
Clinical Efficacy
Commercial AMTAGVI demonstrates impressive clinical responses, particularly in earlier stage patients.
Investor Sentiment
Despite setback, there is significant market and value generating potential for AMTAGVI, and the positive results and KOL conversations at ASCO '25 help reaffirm that position.
Market Adoption
These data are a positive step towards achieving long-term objectives by expanding adoption among physicians and ATCs.
Negative Factors
Financial Performance
The stock has experienced negative pressure due to the lower than expected AMTAGVI revenue and downward revised financial guidance.
Operational Challenges
Operational and logistical challenges with ATCs have continued to persist one year+ into launch.
Regulatory Challenges
The FDA's complete response letter (CRL) regarding REPL's BLA for RP1 + nivolumab in advanced melanoma appears to require a significant amount of time and work to address.

Iovance Biotherapeutics (IOVA) vs. SPDR S&P 500 ETF (SPY)

Iovance Biotherapeutics Business Overview & Revenue Model

Company DescriptionIovance Biotherapeutics, Inc. is a biotechnology company focused on the development and commercialization of innovative cancer immunotherapies. It operates within the healthcare and pharmaceuticals sector, specializing in cell therapy treatments. The company's core products are based on tumor-infiltrating lymphocyte (TIL) technology, which harnesses the power of a patient's immune cells to attack cancer cells, offering potential therapies for patients with various types of cancer including melanoma and cervical cancer.
How the Company Makes MoneyIovance Biotherapeutics generates revenue primarily through the development and potential commercialization of its proprietary TIL therapy products. The company's revenue model is based on bringing these therapies to market either independently or through partnerships with other pharmaceutical companies. Iovance may earn income through licensing agreements, collaboration with other firms, and potential future sales of approved therapies. Additionally, significant partnerships or alliances with larger pharmaceutical companies can provide funding, milestone payments, and royalties, contributing to its revenue streams.

Iovance Biotherapeutics Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 25.24%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a mixed sentiment. While there are significant achievements like strong first-year revenue, successful international compliance, and positive market expansion prospects, these are tempered by challenges such as a decline in first-quarter revenue, manufacturing issues, a cautious revenue outlook, and increased costs.
Q1-2025 Updates
Positive Updates
First Year U.S. Launch Revenue
Generated more than $210 million in revenue in the first 12 months of the U.S. launch of Amtagvi, with infusions from nearly 300 patients.
Successful EMA Inspections
EMA inspected and confirmed that the ICTC and contract manufacturers are GMP-compliant, supporting upcoming EU approval of Amtagvi.
Strong Commercial Network
70 ATCs are part of the treatment network with 79% completing tumor resections, indicating a strong foundation for growth.
Positive Market Expansion Prospects
Anticipated approvals for Amtagvi in the United Kingdom, Canada, and the European Union, with additional submissions in Australia and Switzerland.
Negative Updates
Revenue Decline in First Quarter
First quarter revenue was $49.3 million, lower than previous quarters, due to manufacturing capacity issues and lower Proleukin sales.
Manufacturing Challenges
Higher rates of patient drop-off and lower manufacturing success rates impacted first quarter revenue, although success rates have rebounded.
Revised Revenue Guidance
Revenue guidance was revised to $250 million-$300 million for the full year 2025, reflecting a more conservative outlook.
Increased Cost of Sales
Cost of sales increased significantly due to patient drop-off and manufacturing success rates, impacting gross margin.
Company Guidance
During the Iovance Biotherapeutics First Quarter 2025 Financial Results Conference Call, significant guidance and metrics were outlined. The U.S. commercial launch of Amtagvi generated over $210 million in revenue in its first year, with the first quarter of 2025 alone contributing $49.3 million—$43.6 million from Amtagvi and $5.7 million from Proleukin sales. Despite a reduction in capacity due to scheduled maintenance, there was a record number of production starts in Q2. The revised full-year revenue guidance for 2025 is set between $250 million and $300 million, with expectations for 100-110 commercial patient infusions in Q2. Gross margins are projected to exceed 70% in the coming years. Additionally, the company anticipates potential approvals for Amtagvi in the UK, Canada, and the EU, further expanding its market presence.

Iovance Biotherapeutics Financial Statement Overview

Summary
Iovance Biotherapeutics is experiencing revenue growth but remains unprofitable with significant operational inefficiencies and negative cash flow. Despite a strong equity position and low leverage, the financial stability could be challenged by ongoing losses.
Income Statement
30
Negative
Iovance Biotherapeutics has shown substantial revenue growth with total revenue increasing significantly from $1.18 million in 2023 to $212.68 million in TTM (Trailing-Twelve-Months), marking its first substantial revenue generation. However, despite revenue growth, the company remains unprofitable with a negative net income of $375.36 million in TTM. The gross profit margin is 19.2% in TTM, reflecting that costs are still high relative to revenue. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies and high operating costs.
Balance Sheet
45
Neutral
The balance sheet shows a relatively strong equity position, with a debt-to-equity ratio of 0.07, suggesting low leverage. Stockholders' equity stands at $767.87 million, indicating financial stability. However, the negative net income affects the return on equity, which remains negative. The equity ratio is 79.4%, reflecting a strong capital structure with substantial equity financing.
Cash Flow
40
Negative
The company has a negative operating cash flow of $334.39 million in TTM, demonstrating cash outflows from operations. Free cash flow also remains negative at $347.50 million, indicating challenges in generating cash from operations after capital expenditures. However, the firm successfully raised $340.40 million through financing activities, supporting its cash position.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue164.07M1.19M0.000.000.00
Gross Profit40.08M-9.57M-21.14M-13.98M-8.71M
EBITDA-351.67M-427.43M-374.76M-328.27M-250.87M
Net Income-372.18M-444.04M-395.89M-342.25M-259.58M
Balance Sheet
Total Assets910.43M780.35M663.98M777.33M768.46M
Cash, Cash Equivalents and Short-Term Investments323.78M279.87M471.85M596.00M629.44M
Total Debt58.26M75.86M84.45M71.53M51.66M
Total Liabilities200.02M195.74M164.34M155.67M111.96M
Stockholders Equity710.40M584.61M499.64M621.66M656.50M
Cash Flow
Free Cash Flow-364.05M-384.11M-313.18M-265.51M-251.93M
Operating Cash Flow-352.98M-361.82M-292.76M-227.94M-205.13M
Investing Cash Flow-96.41M-155.24M256.45M132.00K-317.85M
Financing Cash Flow390.66M462.96M190.15M239.27M576.42M

Iovance Biotherapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.97
Price Trends
50DMA
1.98
Positive
100DMA
2.70
Positive
200DMA
5.36
Negative
Market Momentum
MACD
0.27
Negative
RSI
83.51
Negative
STOCH
88.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Positive. The current price of 3.97 is above the 20-day moving average (MA) of 2.09, above the 50-day MA of 1.98, and below the 200-day MA of 5.36, indicating a neutral trend. The MACD of 0.27 indicates Negative momentum. The RSI at 83.51 is Negative, neither overbought nor oversold. The STOCH value of 88.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IOVA.

Iovance Biotherapeutics Risk Analysis

Iovance Biotherapeutics disclosed 81 risk factors in its most recent earnings report. Iovance Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Iovance Biotherapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$722.01M53.85-4.52%92.31%78.17%
57
Neutral
$747.89M-83.24%-100.32%-197.69%
56
Neutral
$792.10M-44.59%-73.79%-5.24%
50
Neutral
AU$2.60B2.95-57.47%2.44%36.73%13.67%
49
Neutral
$1.05B-51.85%11070.12%32.07%
45
Neutral
$789.77M-121.50%-18.75%
45
Neutral
$871.07M-119.66%-551.08%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IOVA
Iovance Biotherapeutics
3.97
-5.16
-56.52%
KALV
KalVista Pharmaceuticals
15.56
1.09
7.53%
VIR
Vir Biotechnology
5.85
-4.25
-42.08%
IMTX
Immatics
6.45
-5.93
-47.90%
NUVB
Nuvation Bio
2.56
-1.05
-29.09%
AMLX
Amylyx Pharmaceuticals Inc
8.39
6.47
336.98%

Iovance Biotherapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Iovance Biotherapeutics Appoints New Chief Financial Officer
Positive
Jul 15, 2025

On July 15, 2025, Iovance Biotherapeutics announced the appointment of Corleen Roche as Chief Financial Officer, effective August 6, 2025. Ms. Roche, who brings over 30 years of experience in the biotech and life sciences industry, will replace Matthew W. Rosinack. Her extensive background in executive financial leadership and product launches is expected to be invaluable as Iovance focuses on revenue growth and advancing its mission of developing novel therapies for cancer patients. This strategic appointment is seen as a significant step for Iovance as it navigates its first commercial launch and aims to strengthen its position in the biotechnology industry.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Executive/Board Changes
Iovance Biotherapeutics CFO Resignation and Interim Appointment
Neutral
Jul 3, 2025

On June 30, 2025, Iovance Biotherapeutics announced the resignation of Jean-Marc Bellemin as Chief Financial Officer, effective immediately, with Matthew W. Rosinack stepping in as interim Principal Financial Officer and Principal Accounting Officer. Rosinack, who has extensive experience in finance roles at various biotechnology and medical device companies, has been with Iovance since September 2021 and will temporarily fill the role as the company navigates this transition.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Iovance Biotherapeutics CFO Resignation Announced
Negative
Jun 13, 2025

On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, announced his resignation effective July 10, 2025, to pursue other opportunities. This departure may impact the company’s financial leadership and strategic direction as it continues to develop cancer immunotherapies.

The most recent analyst rating on (IOVA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
Iovance Biotherapeutics Approves Key Proposals at Annual Meeting
Positive
Jun 10, 2025

On June 10, 2025, Iovance Biotherapeutics held its Annual Meeting of Stockholders virtually, where stockholders voted on five key proposals. These included the election of directors, approval of executive compensation, ratification of Ernst & Young LLP as the accounting firm, and amendments to increase shares in the equity incentive and employee stock purchase plans. All proposals were approved, reflecting strong shareholder support and potentially enhancing the company’s operational flexibility and strategic initiatives.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025